Special Issue

Advances of Precision Medicine in Oncology

Message from the Guest Editors

Precision medicine represents the future for individual diagnostics and therapeutic interventions. Targeted to the molecular basis of cancer, precision oncology uses individual differences to create personalized treatment plans. Hence, it is vital to develop a deep understanding of molecular portraits and advance personalized diagnostics and therapeutic interventions accordingly. This Special Issue focuses on the identification and elucidation of the role of novel biomolecules implicated in cancer progression and the tumor- and metastasis-promoting microenvironment, their clinical applications as cancer biomarkers and the development of novel personalized treatments. We welcome authors to submit papers on malignancies. Submissions should focus on (but are not limited to) the following areas:

- Emerging technologies for cancer biomarker discovery.
- Identification of novel proteins and other biomolecules as cancer biomarkers in diagnostics and the tumour pathways for therapeutics.
- Molecular diagnostic approaches and bioinformatics to guide cancer diagnosis and treatment.
- Clinical applications in precision cancer medicine.
- Circulating tumor cells/DNA in liquid biopsies.

Guest Editors

Dr. Panagiota Filippou

1. School of Health and Life Sciences, Teesside University, Middlesbrough TS1 3BX, UK
2. National Horizons Centre, Teesside University, Darlington DL1 1HG, UK

Dr. Anastasia Constantinidou

1. Medical School, University of Cyprus, Nicosia 1678, Cyprus
2. Bank of Cyprus Oncology Centre, Strovolos 2011, Cyprus
3. Cyprus Cancer Research Institute (CCRI), Nicosia 2116, Cyprus

Deadline for manuscript submissions

25 December 2024

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).